Novel approaches to treat muscular dystrophies (Q34204364)

31 July 2017

1 reference

title

Novel approaches to treat muscular dystrophies (English)

1 reference

ORCID Public Data File 2021

31 July 2017

1 reference

author name string

Walter MC

series ordinal

1

1 reference

31 July 2017

Lochmüller H

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

published in

1 reference

31 July 2017

volume

10

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

695-707

1 reference

Muscular dystrophy: historical overview and classification in the genetic era.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Myotilin, a novel sarcomeric protein with two Ig-like domains, is encoded by a candidate gene for limb-girdle muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Animal models for muscular dystrophy: valuable tools for the development of therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

The childhood muscular dystrophies: making order out of chaos

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Cyclosporine increases muscular force generation in Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Therapies in muscular dystrophy: current concepts and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Anabolic steroids in athletics: How well do they work and how dangerous are they?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Outlook for therapy in the muscular dystrophies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Mitochondrial DNA alterations as a source of human disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Insulin-like growth factor-I and high protein diet decrease calpain-mediated proteolysis in murine muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Commercially marketed supplements for bodybuilding athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Creatine supplementation enhances muscular performance during high-intensity resistance exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Influence of oral creatine supplementation of muscle torque during repeated bouts of maximal voluntary exercise in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Creatine monohydrate increases strength in patients with neuromuscular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

A randomized comparative study of two methods for controlling Tendo Achilles contracture in Duchenne muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

The role of palliative care in advanced muscular dystrophy and spinal muscular atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Ptosis repair in a patient with oculopharyngeal dystrophy: brow suspension using autogenous fascia lata by spinal anaesthesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Cardiac involvement in primary myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Expression of full-length utrophin prevents muscular dystrophy in mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Persistence in muscle of an adenoviral vector that lacks all viral genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Myoblast transfer in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Immunobiology and the future of myoblast transfer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Muscle regeneration by bone marrow-derived myogenic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Creatine supplementation in endurance sports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

Respiratory muscle aids for the prevention of pulmonary morbidity and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.695

10.1517/13543784.10.4.695

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference